Kailera Therapeutics, Inc.

Research Kailera Therapeutics, Inc. (KLRA) on Bullrun: market cap USD 2.81B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerKLRA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.81B
• Financial periodQ1 2026
• Net income-USD 78.87M
• Free cash flow-USD 68.31M

Valuation Snapshot

latest market cap is USD 2.81B.

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.

Frequently asked questions

What is Kailera Therapeutics, Inc.'s market cap?

Kailera Therapeutics, Inc.'s market capitalization is USD 2.81B.

What does Kailera Therapeutics, Inc. do?

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.